Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
6 evidence topics · 7 sources
Ersodetug: primary endpoint and success threshold in upLIFT, preliminary
Ersodetug: additional outcomes measured in upLIFT
Ersodetug: outcomes in the peer-reviewed expanded access series
“Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ersodetug: manufacturer-described outcomes of expanded access use
Current multimodal therapy in metastatic insulinoma: hypoglycemia control and survival
“The final cohort comprised 275 patients with individual-level data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The liver was the predominant metastatic site (89.5%), while 82.8% of patients (111/134 evaluable) required nutritional support, reflecting the profound endocrine and metabolic burden of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A disease control rate of 69.9% (153 evaluable) was observed with multimodal therapy, and definitive hypoglycemia control was achieved in 62.1% (164/264) of patients at last follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival from the time of metastatic diagnosis was 84 months (95% CI: 61.8-111), with a subset of patients surviving beyond 25 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This compares to previous reports of median survival of about 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypoglycemia was well-controlled and did not cause the deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Current therapy in NICTH: recovery and mortality
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In light of a high mortality rate, approximating 23%, identifying and comprehensively evaluating prognostic factors is paramount and necessitate further investigative efforts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote